| Preface |
|
iii | |
| Contributors |
|
xi | |
|
Regulatory Toxicology Testing: Laboratories and Good Laboratory Practices |
|
|
1 | (14) |
|
|
|
|
|
1 | (1) |
|
Study Monitor/Sponsor Representative and the Audit |
|
|
1 | (1) |
|
Background of the Good Laboratory Practices |
|
|
2 | (1) |
|
Conducting the Preplacement Audit |
|
|
3 | (5) |
|
Case Study of Noncompliance |
|
|
8 | (4) |
|
|
|
12 | (1) |
|
|
|
13 | (2) |
|
Laboratory Animals and In Vitro Test Systems Used in Regulatory Toxicology |
|
|
15 | (18) |
|
|
|
|
|
15 | (1) |
|
Use of Animals in Toxicology Testing |
|
|
15 | (2) |
|
Common Species in Regulatory Toxicology |
|
|
17 | (9) |
|
In Vitro Test Systems in Regulatory Toxicology Testing |
|
|
26 | (3) |
|
|
|
29 | (4) |
|
|
|
33 | (46) |
|
|
|
|
|
Background and Basic Principles |
|
|
33 | (7) |
|
Assessment of Major Organ Functions |
|
|
40 | (19) |
|
|
|
59 | (4) |
|
|
|
63 | (1) |
|
|
|
64 | (1) |
|
|
|
65 | (14) |
|
Metabolism and Toxicokinetics |
|
|
79 | (30) |
|
|
|
|
|
79 | (2) |
|
Study Design and Study Parameters |
|
|
81 | (11) |
|
Data Evaluation and Interpretation |
|
|
92 | (10) |
|
|
|
102 | (2) |
|
|
|
104 | (5) |
|
Toxicologic Pathology Assessment |
|
|
109 | (26) |
|
|
|
|
|
109 | (1) |
|
|
|
109 | (16) |
|
|
|
125 | (5) |
|
|
|
130 | (5) |
|
|
|
135 | (14) |
|
|
|
|
|
|
|
135 | (4) |
|
|
|
139 | (3) |
|
Dermal Irritation Studies |
|
|
142 | (3) |
|
|
|
145 | (1) |
|
|
|
146 | (3) |
|
Multidose General Toxicology Studies |
|
|
149 | (36) |
|
|
|
|
|
|
|
149 | (2) |
|
Study Design and Study Parameters |
|
|
151 | (12) |
|
Data Reporting, Analysis, Interpretation, and Risk Assessment |
|
|
163 | (11) |
|
|
|
174 | (6) |
|
|
|
180 | (1) |
|
|
|
181 | (4) |
|
|
|
185 | (64) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
185 | (3) |
|
Bacterial Mutation Assays |
|
|
188 | (12) |
|
Mammalian Cell Mutation Assays |
|
|
200 | (7) |
|
In Vitro Chromosome Aberration Assays |
|
|
207 | (8) |
|
In Vivo Cytogenetics Assay Systems |
|
|
215 | (7) |
|
Primary DNA Damage Assays |
|
|
222 | (6) |
|
Syrian Hamster Embryo Cell Transformation Assay |
|
|
228 | (7) |
|
Single Cell Gel Electrophoresis (Comet Assay) |
|
|
235 | (1) |
|
Implication of Positive Genetox Findings |
|
|
236 | (3) |
|
|
|
239 | (10) |
|
|
|
249 | (16) |
|
|
|
|
|
249 | (3) |
|
Traditional Study Design and Parameters Measured |
|
|
252 | (2) |
|
Data Reporting, Analysis, Interpretation, and Risk Assessment |
|
|
254 | (5) |
|
Ongoing Issues and Future Trends |
|
|
259 | (1) |
|
|
|
259 | (6) |
|
Juvenile Animal Toxicology Studies |
|
|
265 | (40) |
|
|
|
|
|
265 | (2) |
|
Study Design and Study Parameters |
|
|
267 | (19) |
|
Data Reporting, Analysis, Interpretation, and Risk Assessment |
|
|
286 | (7) |
|
|
|
293 | (1) |
|
|
|
294 | (11) |
|
Developmental and Reproductive Toxicology |
|
|
305 | (52) |
|
|
|
|
|
305 | (3) |
|
Study Design and Study Parameters |
|
|
308 | (13) |
|
Data Compilation, Interpretation, and Risk Assessment |
|
|
321 | (15) |
|
Additional Parameters to Measure and Other Follow-Up Studies |
|
|
336 | (3) |
|
|
|
339 | (1) |
|
Appendix: Commonly Used Terms in Reproductive and Developmental Toxicity |
|
|
339 | (10) |
|
|
|
349 | (8) |
|
|
|
357 | (34) |
|
|
|
|
|
Introduction: What Is Neurotoxicity? |
|
|
357 | (3) |
|
Adult Neurotoxicity Testing: Study Design |
|
|
360 | (6) |
|
Developmental Neurotoxicity Testing: Study Design |
|
|
366 | (9) |
|
Data Collection, Reporting, Evaluation, and Interpretation |
|
|
375 | (10) |
|
|
|
385 | (1) |
|
|
|
386 | (5) |
|
Toxicological Assessment of the Immune System |
|
|
391 | (26) |
|
|
|
|
|
|
|
|
|
Introduction---Overview of the Immune System |
|
|
391 | (3) |
|
Immunosuppression, Hypersensitivity, and Autoimmunity |
|
|
394 | (2) |
|
Considerations and Approaches for Detecting Immunosuppression |
|
|
396 | (2) |
|
Dosing and Species Considerations |
|
|
398 | (1) |
|
Approaches to Evaluating Humoral Immunity |
|
|
398 | (2) |
|
Approaches to Evaluating Cellular Immunity |
|
|
400 | (1) |
|
Approaches to Evaluating Nonspecific Immunity: Macrophages, NK Cells, and Neutrophils |
|
|
401 | (1) |
|
Approaches to Evaluating Hypersensitivity Responses |
|
|
402 | (1) |
|
Developmental Immunotoxicity |
|
|
403 | (1) |
|
Immunomodulation in Human Populations |
|
|
404 | (1) |
|
Regulatory Issues in Immunotoxicology |
|
|
405 | (5) |
|
Conclusions/Further Directions |
|
|
410 | (1) |
|
|
|
411 | (6) |
|
Inhalation and Pulmonary Toxicity Studies |
|
|
417 | (22) |
|
|
|
|
|
417 | (1) |
|
Contracting an Inhalation Study |
|
|
418 | (3) |
|
|
|
421 | (6) |
|
|
|
427 | (3) |
|
|
|
430 | (2) |
|
|
|
432 | (1) |
|
Characterizing the Effects of Exposure |
|
|
433 | (3) |
|
The Report and Data Interpretation |
|
|
436 | (1) |
|
|
|
437 | (2) |
|
Cancer Risk Assessment of Environmental Agents: Approaches to the Incorporation and Analysis of New Scientific Information |
|
|
439 | (26) |
|
|
|
|
|
|
|
|
|
439 | (3) |
|
Hazard Identification/Hazard Characterization |
|
|
442 | (8) |
|
Dose-Response Assessment/Dose-Response Characterization |
|
|
450 | (5) |
|
Emerging Directions in Exposure Assessment |
|
|
455 | (3) |
|
|
|
458 | (1) |
|
|
|
459 | (1) |
|
|
|
460 | (5) |
|
Nonclinical Safety Testing of Pharmaceuticals |
|
|
465 | (14) |
|
|
|
|
|
|
|
465 | (1) |
|
Direction on the Timing of Toxicology Studies in Relation to Clinical Trials |
|
|
466 | (2) |
|
Studies Needed for Most New Drug Products |
|
|
468 | (3) |
|
|
|
471 | (1) |
|
|
|
472 | (2) |
|
Studies for Previously Approved Drugs |
|
|
474 | (1) |
|
The Value of Nonclinical Testing? |
|
|
475 | (1) |
|
Summary and Future Directions |
|
|
476 | (1) |
|
|
|
476 | (3) |
|
Health Risk Assessment Strategies in the Food and Cosmetic Industry |
|
|
479 | (12) |
|
|
|
|
|
|
|
479 | (1) |
|
|
|
479 | (9) |
|
International Regulations |
|
|
488 | (1) |
|
|
|
489 | (1) |
|
|
|
489 | (2) |
| Index |
|
491 | |
Lisainfo e-raamatute kohta